Trial
NCT03926143
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bayer
Collaborators
—
Condition
Solid Tumors
Intervention
BAY94-9343 (Anetumab ravtansine)
Why stopped
Due to strategic company decisions, the development of anetumab ravtansine was stopped.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-04